Datopotamab Deruxtecan Biologics License Application Accepted in the US for Patients with Previously Treated Metastatic HR-Positive, HER2-Negative Breast Cancer
2 April 2024 -- AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with unresectable or metastatic hormone receptor...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: AstraZeneca | Breast Cancer | Cancer | Cancer & Oncology | Drugs & Pharmacology | HER2 | Hormones | New Drug Applications